{
    "clinical_study": {
        "@rank": "55209", 
        "arm_group": {
            "arm_group_label": "Vemurafenib", 
            "arm_group_type": "Experimental", 
            "description": "Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days)."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out what effects, good and/or bad, treatment with\n      vemurafenib (also known as Zelboraf\u2122) has on the patient and on  leukemia. Specifically, the\n      researchers want to know how well vemurafenib eliminates leukemia from the blood."
        }, 
        "brief_title": "BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hairy Cell Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Hairy Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2265 18 years of age\n\n          -  Histologically confirmed classical HCL with one of the following:\n\n          -  Intolerance to purine analogs\n\n          -  Failure to achieve any response (CR or PR) to the initial purine analog-based therapy\n\n          -  Relapse \u2264 2 years of purine analog-based therapy\n\n          -  \u2265 2 relapses Histologic confirmation of diagnosis will be performed at MSKCC or a\n             participating site.\n\n          -  Patients who meet the standard treatment initiation criteria, as defined by ANC \u22641.0,\n             Hgb \u2264 10.0 or PLT \u2264100K\n\n          -  ECOG performance status of 0-2\n\n          -  Acceptable pre-study organ function during screening as defined as: Total bilirubin \u2264\n             1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and\n             alanine aminotransferase (ALT) \u2264 2.5x ULN, and serum creatinine \u2264 1.5x ULN\n\n          -  Electrocardiogram (ECG) without evidence of clinically significant ventricular\n             arrhythmias or ischemia as determined by the investigator and a rate-corrected QT\n             interval (QTc, Bazett's formula) of < 480 msec.\n\n          -  For women of childbearing potential, agreement to the use of two acceptable methods\n             of contraception, including one barrier method, during the study and for 6 months\n             after discontinuation of vemurafenib\n\n          -  For men with female partners of childbearing potential, agreement to use a latex\n             condom and to advise their female partner to use an additional method of\n             contraception during the study and for 6 months after discontinuation of vemurafenib\n\n          -  Negative serum pregnancy test within 7 days of commencement of treatment in\n             premenopausal women.\n\n          -  Agreement not to donate blood or blood products during the study and for at least 6\n             months after discontinuation of vemurafenib; for male partners, agreement not to\n             donate sperm during the study and for at least 6 months after discontinuation of\n             vemurafenib\n\n          -  Ability to understand and willingness to sign a written informed consent document.\n\n          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory\n             tests, and other study procedures.\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast-feeding\n\n          -  Have had chemotherapy (including purine analogs, rituximab, and other investigational\n             agents) within six weeks prior to entering the study\n\n          -  Major surgery within 4 weeks prior to entering the study\n\n          -  Invasive malignancy within the past 2 years prior to first study drug administration,\n             except for adequately treated (with curative intent) basal or squamous cell\n             carcinoma, melanoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma\n             of the breast, in situ prostate cancer, or limited stage bladder cancer or other\n             cancers from which the patient has been disease-free for at least 2 years\n\n          -  Refractory nausea or vomiting, malabsorption, external biliary shunt, or history of\n             any type of gastrointestinal surgery that would preclude adequate absorption of study\n             drug\n\n          -  Prior treatment with MEK or BRAF inhibitors\n\n          -  Active HIV, hepatitis B and hepatitis C\n\n          -  Patients with HCL variant (as defined by absence of expression of CD25 or absence of\n             BRAF V600E mutation)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711632", 
            "org_study_id": "12-200"
        }, 
        "intervention": {
            "arm_group_label": "Vemurafenib", 
            "description": "Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Patients who achieve CR with MRD or PR may be retreated with vemurafenib for up to 3 additional cycles at the treating physician's discretion. Patients who achieve a CR without MRD will be observed, and will be treated with vemurafenib for up to 3 additional cycles at the time of relapse (either hematologic or by MRD). Patients who are re-treated after observation will follow the treatment/evaluation plan of Cycles 1-3, except the Cycle 1 Week 1-3 research bloods and Cycle 2 Day 1research bone marrow biopsy and/or aspirate. Patients who achieve no response after the initial 3 cycles of vemurafenib will be removed from the study.", 
            "intervention_name": "Vemurafenib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "VEMURAFENIB (PLX4032 or R05185426)", 
            "BRAF Inhibitor", 
            "12-200"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Alan Saven, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92037"
                    }, 
                    "name": "Scripps Clinic"
                }, 
                "investigator": {
                    "last_name": "Alan Saven, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Robert Stone, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Robert Stone, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jae Park, MD", 
                    "phone": "212-639-4048"
                }, 
                "contact_backup": {
                    "last_name": "Martin S. Tallman, MD", 
                    "phone": "212-639-3842"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Jae Park, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Michael Grever, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Ohio State University"
                }, 
                "investigator": {
                    "last_name": "Michael Grever, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia", 
        "overall_contact": {
            "last_name": "Jae H Park, MD", 
            "phone": "212 639-4048"
        }, 
        "overall_contact_backup": {
            "last_name": "Martin S. Tallman, MD", 
            "phone": "212 639-3842"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Jae H. Park, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "as assessed by overall response rates after three months of treatment in patients with relapsed or refractory HCL.", 
            "measure": "efficacy of vemurafenib", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711632"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Toxicity will be graded and recorded using the NCI Common Toxicology Criteria version 4.0.", 
                "measure": "Toxicity (safety and tolerability)", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Peripheral blood and/or bone marrow aspirate samples from pretreatment and post-treatment at specified time points will be assessed by Western Blot or by phospho-flow for the downstream targets of BRAF (MEK, pMEK, ERK, pERK) to assess the ontarget effect of the Vemurafenib.", 
                "measure": "To assess the pharmacodynamics", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Reactivation of MAPK pathways: Increased expression of the other RAF isoforms CRAF and ARAF), and MAPK (MAPK8 or COT) will be analyzed by Western Blot and/or real-time PCR39,40. Secondary BRAF mutations (all 18 BRAF exons) and RAS mutations40 will be analyzed by bidirectional Sanger sequencing and by Raindance multiplex PCR and Illumina next generation sequencing, respectively. Activation of RTKs (i.e. PDGFR\u03b2 and IGF-IR) will be assessed by Western Blot. Cell Biosciences NanoPro 1000 technology will be used to examine quantitative signaling on the entire MAPK, PI3K and JAK-STAT pathways41.", 
                "measure": "evaluate biomarkers", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Northwestern University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ohio State University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Dana-Farber Cancer Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Scripps Clinic", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "North Shore Long Island Jewish Health System", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}